Drug-related hepatotoxicity.

@article{Navarro2006DrugrelatedH,
  title={Drug-related hepatotoxicity.},
  author={V. Navarro and J. Senior},
  journal={The New England journal of medicine},
  year={2006},
  volume={354 7},
  pages={
          731-9
        }
}
Given its rarity, drug-related hepatotoxicity may not be seen during the initial clinical trials of a new medication. After approval, when many more patients are exposed, toxic effects that are very infrequent may emerge. This review explains the difficulties in identifying the cause of hepatotoxic effects in such situations and provides clinical guidance with regard to the detection, evaluation, and possible prevention of drug-related hepatotoxicity. 
Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension.
TLDR
Liver toxicity is the most common reason for drug withdrawals and may not be detected in pre-marketing clinical trials, but in the case of drugs developed for orphan diagnoses, the clinical trial experience is invariably poor. Expand
Nonsteroidal anti-inflammatory drug-induced hepatoxicity.
TLDR
Nonsteroidal anti-inflammatory drugs are among the most prescribed medications worldwide and are considered the most common medications associated with drug-induced liver injury mainly through an idiosyncratic form of hepatotoxicity. Expand
Drug-induced liver disease.
  • T. Davern
  • Medicine
  • Clinics in liver disease
  • 2012
TLDR
Several areas that are potentially vexing for both the novice and cognoscenti are touched on, with the goal of guiding the consultant through one of the most challenging areas of hepatology. Expand
Drug hepatotoxicity from a regulatory perspective.
  • J. Senior
  • Medicine
  • Clinics in liver disease
  • 2007
This article summarizes problems of drug-induced liver injury (DILI), as seen from the perspective of the Food and Drug Administration (FDA). After brief consideration of the scope of FDA activitiesExpand
Antituberculosis Drug-Induced Hepatotoxicity: Incidence, Mechanism and Management
TLDR
Hydrazine, a toxic metabolite of isoniazid, is responsible for hepatotoxicity, the first or the second most reported ADR resulting in treatment interruption. Expand
Hepatotoxicity of Antibacterials: Pathomechanisms and Clinical Data
TLDR
The pattern of antibacterial DILI is reviewed and detail is provided on molecular mechanisms and toxicogenomics, as well asclinical data based on epidemiology studies, to increase the awareness and understanding of druginduced liver injury (DILI) due to antibacterial drugs. Expand
Cancer chemotherapy I: hepatocellular injury.
TLDR
An awareness of the toxic potential of each chemotherapeutic agent is necessary before initiation of new oncologic treatments, and the risks that the oncologist and the patient are willing to assume are high. Expand
Hepatotoxicity and Hepatic Dysfunction
TLDR
In the setting of multiple therapeutic modalities, chemotherapy is the most widely used one because the metabolism and clearance of chemotherapy drugs are mostly dependent on normally functioning kidney and liver. Expand
Influence of allopurinol on thiopurine associated toxicity: A retrospective population‐based cohort study
TLDR
The aims of this study were to evaluate rates of hepatotoxicity, myelot toxicity, pancreas toxicity and therapy persistence in adult thiopurine users with or without allopurinol. Expand
Drug induced hepatotoxicity: data from the Serbian pharmacovigilance database
The main aim of this study was to determine the most frequently reported drugs to the Serbian Pharmacovigilance Database (SPD) with suspected induced hepatotoxicity. Additionally, reasons for the lowExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 66 REFERENCES
Drug-induced hepatotoxicity.
  • W. M. Lee
  • Medicine
  • The New England journal of medicine
  • 1995
Causality assessment in drug-induced hepatotoxicity
TLDR
The use of diagnostic algorithms may add consistency to the diagnostic process either by translating the suspicion into a quantitative score or by providing a framework that emphasises the features that merit attention in cases of suspected hepatic adverse reactions. Expand
Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis.
TLDR
In some instances, as in paracetamol poisoning, the prompt onset of the disease, the dose-relationship and the absence of hypersensitivity manifestations clearly indicate direct toxicity, but in many other instances, clinical features suggest an immunoallergic mechanism. Expand
Idiosyncratic drug reactions: the reactive metabolite syndromes
TLDR
Research is needed to explore further the pathophysiology of idiosyncratic drug reactions, so that better diagnostic tests and treatment methods can be developed. Expand
Genetic predisposition to drug-induced hepatotoxicity.
TLDR
There is now evidence indicating that genetic variations in systems of biotransformation or detoxication may modulate either the toxic or sensitizing effects of some drugs. Expand
Epidemiology and individual susceptibility to adverse drug reactions affecting the liver.
  • D. Larrey
  • Medicine
  • Seminars in liver disease
  • 2002
TLDR
Important directions for the future include prospective studies of the incidence of hepatic adverse drug reactions, finding specific markers that augment or replace causality assessment, and further elucidating the role of the genetic and environmental factors that contribute to individual susceptibility. Expand
Drug-Induced Liver Injury
  • G. Abboud, N. Kaplowitz
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2004
TLDR
Mitigating the potential for drug-induced liver injury is achieved by the identification of toxicity signals during clinical trials and the monitoring of liver tests in clinical practice. Expand
Insight into hepatotoxicity: The troglitazone experience
TLDR
In the 4 years since the withdrawal of troglitazone, there has been a major increase in interest in drug induced liver disease (DILI) and the sense of urgency within industry to improve means of screening out liver liabilities at early phases of drug development. Expand
Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions
TLDR
There is need for prospective safety studies to establish the true incidence of DILI caused by a drug, to identify risk factors for it, and to collect biologic materials for analytic studies toward better understanding mechanisms of D ILI. Expand
Comparison of two clinical scales for causality assessment in hepatotoxicity
TLDR
The CIOMS scale showed better discriminative power and produced assessments closer to those of specialists, while the M&V scale was poor in reactions with long latency periods, evolution to chronicity after withdrawal, or death. Expand
...
1
2
3
4
5
...